ClinicalTrials.gg
RecruitingNCT06122233Updated Apr 4, 2025

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

An interventional study of Pulmonary Fibrosis self-management package and smartphone application in Lung Diseases, Interstitial and Pulmonary Fibrosis, sponsored by University of Sydney. Recruiting at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Primary conditionPulmonary FibrosisRegistry: Lung Diseases, InterstitialReclassifiedWhy we changed it
Registry
Lung Diseases, Interstitial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Fibrosis
Why
  1. The study's listed conditions name Pulmonary Fibrosis, a narrower term within Lung Diseases, Interstitial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Sydney · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Pulmonary Fibrosis with a site in Australia — 5 open to participants now, 9 under way, 3 of them phase 3. Pulmonary Fibrosis · Australia.

Planned enrollment
7th of 24
400 · median 206
Started
2024
with 3 others
No phase
2 of 26
2 open now
Registered
20th of 26
by date
Lead sponsor
2 of 26
University of Sydney

Among the 26 studies in Pulmonary Fibrosis with a site in Australia, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2024, is one of 2 with no phase, and was the 20th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

5 of the 26 studies in Pulmonary Fibrosis with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pulmonary Fibrosis with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease (ILD). The main question it aims to answer is:

  • Does REBUILD-SM improve health-related quality of life, symptoms, anxiety, self-efficacy and physical activity for people with ILD?

Participants in the intervention group will work through the self-management package with support from a healthcare professional via phone or Zoom. They will also enter deidentified health data into the RE-BUILD smartphone app to track their progress over time. Participants in the control group will use a reduced functionality version of the smartphone app only.

Researchers will compare both groups to see if there is any difference in health-related quality of life, symptoms, anxiety, self-efficacy and level of physical activity.

Read the detailed description

This study compares REBUILD-SM with standard care in people with ILD. REBUILD-SM comprises a purpose-built smartphone app that allows subjects to enter and track health data over time and an integrated self-management package.

Participants will enter their respiratory diagnosis, medications and side effects, weight, lung function test results, oxygen saturation level and supplemental oxygen usage into the smartphone app. They will also complete questionnaires at specific timepoints using the app. Participants will input most of this data at the beginning of the trial and update it when it changes, for example, after obtaining a new lung function result, starting a new medication, or getting a new side effect from an existing medication. Entering data into the app is expected to take around 30 minutes at the start of the trial, and about 20 minutes at 12, 26 and 52 weeks when completing the questionnaires. Updating data is expected to take about 5-10 minutes and will only happen when there is a change, for example, once per week, although it may not be this frequent.

The app will not provide any recommendations on the health data participants enter - it is simply for recording purposes. To ensure data collection is as complete as possible, electronic reminders will be sent to participants when questionnaires are not completed at the specified timepoints and will alert the study team if the participant fails to complete the questionnaires after the reminder. This will prompt a phone call from a member of the study team to encourage the participant to complete the endpoints. App analytics will be used in the data analysis phase (after the trial is over) to understand how participants have engaged with the app.

Participants in the intervention group will be asked to log into and use the self-management website or view the content via the REBUILD app with support from the study team. The self-management content includes 13 modules and has been designed in collaboration with people with ILD to help increase their ability to self-manage their chronic disease.

During the intervention period, participants will receive four phone calls from a health professional involved in the management of people with ILD to help them set health-related goals and identify appropriate modules from the website to help achieve these goals. These four phone calls are expected to take about 15-30 minutes each.

Each module provides information regarding the topic and provides access to relevant websites, fact sheets, booklets, videos and webinars as well as other external resources. Participants will have direct access to these external resources from within the package through hyperlinks embedded in the title of each resource. Participants are expected to work through their selected modules at their own pace - there is no specific amount of time they are required to allocate to the intervention, and they can utilize as many or as few of the resources as they like.

03

Conditions studied

  • Lung Diseases, Interstitial
  • Pulmonary Fibrosis

Browse trials for

Keywords

  • Self-Management
  • Chronic diseases
04

In context

Pulmonary Fibrosis Reclassified

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

This study's planned enrollment of 400 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.

Browse Pulmonary Fibrosis studies →

Lead sponsor

University of Sydney is the lead sponsor of 94 studies on the registry; 26 are open to participants now.

Compared within Pulmonary Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Interstitial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of fibrotic ILD
  • In possession of a smartphone/tablet and an email address
  • Able to understand written and spoken English
  • Adequate digital literacy to complete requirements of trial
  • On stable ILD treatment for 30 days prior to enrolment

Exclusion criteria

Exclusion Criteria:

  • Not in possession of a smartphone/tablet
  • Insufficient digital literacy to complete requirements of trial
  • Unable to communicate in written/spoken English
  • Not on stable ILD treatment for 30 days prior to enrolment
  • Acute exacerbation within 30 days prior to enrolment
  • Participating in pulmonary rehab at enrolment or during 12-week intervention period
  • Unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    REBUILD-SM Group

    Participants randomised to the intervention will receive the self-management package, including the REBUILD app. Structured self-management support via telephone or Zoom call will be provided 4 times during the 12-week intervention period.

    Behavioral: Pulmonary Fibrosis self-management package and smartphone application

  • No intervention
    Standard Care Group

    In the control arm, participants will receive standard care and a reduced capability version of the REBUILD app to be used for data-capture only. They will also receive phone/Zoom calls at the same frequency during the 12-week intervention period, but no health advice will be given. After 26 weeks, participants in this group will receive access to the fully functional REBUILD app, however they will not receive the self-management content or the support phone calls provided to the intervention group.

Interventions

  • BehavioralPulmonary Fibrosis self-management package and smartphone application

    The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis. The RE-BUILD app is used as a tool for data collection and to help participants self-monitor their disease over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data close to the participant as well as physical activity level (step count). The app also has links to ILD-related educational resources.

    Also known as: REBUILD-SM

07

What researchers measure

Primary outcomes

  1. Change in King's Brief Interstitial Lung Disease (K-BILD) questionnaire score

    Score range 0 - 100; higher score corresponding to better outcome.

    Time frame: Baseline and 12 weeks post-randomisation

Secondary outcomes

  1. Change in K-BILD score

    As above

    Time frame: 26 and 52 weeks post-randomisation

  2. Change in European Quality of Life 5-Dimensions 5-Level (EQ-5D-5L) questionnaire score

    Score range 11111 - 55555; 0-100; higher score indicating worse outcome

    Time frame: Baseline, 12, 26 and 52 weeks post-randomisation

  3. Change in General Self-Efficacy Scale score

    Score range 10 - 40; higher score indicating low level of perceived self-efficacy

    Time frame: Baseline, 12, 26, and 52 weeks post-randomisation

  4. Change in Dyspnoea-12 score

    Score range 0-36; higher score corresponding to greater level of dyspnoea

    Time frame: Baseline, 12, 26 and 52 weeks post-randomisation

  5. Change in Hospital Anxiety and Depression Scale score

    Score range 0-21 (for anxiety and depression); higher scores corresponding to severe anxiety and/or depression

    Time frame: Baseline, 12, 26 and 52 weeks post-randomisation

  6. Change in physical activity levels

    Change in steps per day and change in time spent in the four intensity categories (inactive, low, medium and high activity) will be measured using a physical activity monitor

    Time frame: Baseline, 12 and 52 weeks post-randomisation

  7. Uptake/ changes to ILD treatments

    Includes changes to medications, commencement or change in supplemental oxygen use, participation in pulmonary rehab

    Time frame: Baseline, 12, 26 and 52 weeks post-randomisation

  8. Change in mHealth App Usability questionnaire (MAUQ) score

    Score range 18-126; higher score indicating greater satisfaction with the REBUILD app

    Time frame: 12, 26 and 52 weeks post-randomisation

  9. Change in e-Health Literacy (eHEALS) questionnaire score

    Score range 8-40; higher score indicating higher degree of perceived e-health literacy

    Time frame: Baseline,12 and 52 weeks post-randomisation

  10. Health Care Climate questionnaire

    Score range 6-42; higher score indicating greater satisfaction with treating team

    Time frame: 12 weeks post-randomisation

08

Study locations

4 of 4 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — Deidentified data will be placed in a secure repository for future analysis.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will be available at the end of the trial (approx. April 2028).

Access criteria: Requires ethical approval

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.

Of 41 interventional studies with no phase under Pulmonary Fibrosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 81. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2023
First posted
Nov 8, 2023
StartActual
Jun 3, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06122233
Lead sponsor
University of Sydney
Collaborators
Monash University, Lung Foundation Australia, University of Tasmania
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Jun 3, 2024
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Apr 4, 2025

Study contacts

Carly Barton
Contact
Carly.Barton@Sydney.edu.au
+61 2 9515 5682
Tamera Corte
principal investigator · University of Sydney
Dan Chambers
principal investigator · The University of Queensland
Nicole Goh
principal investigator · Institute of Breathing and Sleep
Ian Glaspole
principal investigator · The Alfred

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion